Price Alert

MaxCyte Inc. (MXCT)

NASDAQ: MXCT · Real-Time Price · USD

1.36

-0.05 (-3.55%)

At close: Aug 15, 2025, 3:40 PM

-3.55% (1D)

Bid	1.36
Market Cap	145.52M
Revenue (ttm)	35.75M
Net Income (ttm)	-44.77M
EPS (ttm)	-0.42
PE Ratio (ttm)	-3.25
Forward PE	-3.95
Analyst	Hold

Ask	1.37
Volume	635,011
Avg. Volume (20D)	884,745
Open	1.43
Previous Close	1.41
Day's Range	1.35 - 1.45
52-Week Range	1.26 - 5.20
Beta	0.27

About MXCT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MXCT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MXCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

MaxCyte has released their quartely earnings on Aug 6, 2025:

Revenue of $8.51M misses estimates by $1.21M, with -18.43% YoY decline.

EPS of -0.12 misses estimates by -0.02, with -33.33% YoY decline.

Next Earnings Release

MaxCyte Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-29.9%

MaxCyte shares are trading lower after the company... Unlock content with Pro Subscription

7 months ago

+11.59%

MaxCyte shares are trading higher after the company announced expectations for a year-over-year increase in Q4 and FY24 revenue

News

1 week ago · seekingalpha.com

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Douglas J. Swirsky - Chief Financial Officer Maher Masoud - President, CEO & Executive Dire...

1 week ago · fool.com

MaxCyte (MXCT) Q2 Revenue Drops 18%

1 week ago · zacks.com

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.09 per share a year ago.

1 month ago · businesswire.com

PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan

TOKYO--(BUSINESS WIRE)--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corpor...